Dr. Alan Barge is the Chairman of Modra Pharmaceuticals, the founder of Carrick Therapeutics and the Co-Founder of ASLAN Pharmaceuticals. Alan is the former VP of Clinical and Head of Oncology and Infection, AstraZeneca

Dr. Barge trained in medicine at Oxford and London and specialized in oncology and hematology. He joined Amgen in 1990, as European Medical Director, and was responsible for the European, and subsequently worldwide development of Neupogen® (filgrastim), and other hematopoietic growth factors. In 1999, he joined AstraZeneca, where he established a team responsible for early phase oncology drug development. In 2005, he was appointed Vice President of Clinical and Head of Oncology and Infection, responsible for building and managing a large development group, and the execution of AstraZeneca’s oncology portfolio globally.